Pharmacokinetics and Pharmacodynamics of Interferon Alpha 2A
NCT01228422 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 24
Last updated 2010-10-26
Summary
The aim was to verify the Pharmacokinetics and Pharmacodynamics of alpha interferon product-2A - Blausiegel, taking as the comparator drug product Roferon ® A (interferon alpha-2A - Roche Laboratory).
Conditions
- Healthy
Interventions
- BIOLOGICAL
-
Interferon alpha 2a
3MUI
Sponsors & Collaborators
-
Azidus Brasil
lead INDUSTRY
Principal Investigators
-
Alexandre Frederico, Doctor · Azidus Brasil
Eligibility
- Min Age
- 18 Years
- Max Age
- 55 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2009-03-31
- Primary Completion
- 2009-08-31
- Completion
- 2009-08-31
Countries
- Brazil
Study Locations
More Related Trials
-
Low-dose IL-2( Interleukin-2) Treatment in SLE
NCT02084238 ·Status: COMPLETED ·Phase: NA
-
Phase IIa Study for IPG11406 in Patients With Lupus Nephritis
NCT06717815 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
The Iguratimod Effect on Lupus Nephritis (IGeLU)
NCT02936375 ·Status: UNKNOWN ·Phase: PHASE2
-
A Phase II Study to Evaluate the Efficacy and Safety of SHR-1314 in Lupus Nephritis
NCT04924296 ·Status: UNKNOWN ·Phase: PHASE2
-
A Study of SHR-2173 in Participants With Systemic Lupus Erythematosus
NCT07299422 ·Status: RECRUITING ·Phase: PHASE2
-
Inaticabtagene Autoleucel Injection in the Treatment of Refractory Systemic Lupus Erythematosus-related Immune Thrombocytopenia
NCT06826430 ·Status: RECRUITING ·Phase: PHASE1
-
Evaluation of the Tolerance, Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of MIL62 Injection for Treating Lupus Nephritis
NCT07044115 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
Efficacy and Safety of Low-dose IL-2 in Patients With SLE: a Multicenter, Randomised, Placebo-controlled Trial
NCT04077684 ·Status: COMPLETED ·Phase: PHASE2
-
Interferon Signature in Anti-CTLA-4 and Anti-PD-1/PD-L1-Treated Cancer Patients Compared With Systemic Autoimmune Disease Patients
NCT07249060 ·Status: RECRUITING
-
Efficacy and Safety of Two Doses of Anifrolumab Compared to Placebo in Adult Subjects With Active Systemic Lupus Erythematosus
NCT02446912 ·Status: COMPLETED ·Phase: PHASE3
-
Phase IIb Study of IFN-K in Systemic Lupus Erythematosus
NCT02665364 ·Status: TERMINATED ·Phase: PHASE2
-
Study of Leukocyte Populations in Patients With Chronic Inflammatory
NCT04749875 ·Status: NOT_YET_RECRUITING
-
Long Term Safety of Anifrolumab in Adult Subjects With Active Systemic Lupus Erythematosus
NCT02794285 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of rhuMAb IFNalpha in Adults With Systemic Lupus Erythematosus
NCT00541749 ·Status: COMPLETED ·Phase: PHASE1
-
Exploratory Clinical Study on the Safety of STR-P004
NCT07143617 ·Status: RECRUITING ·Phase: NA
-
A Study of D-2570 in Patients With Active Systemic Lupus Erythematosus (SLE)
NCT07311200 ·Status: RECRUITING ·Phase: PHASE2
-
Single and Multiple Ascending Dose Study in Healthy Participants and Participants With an Autoimmune Disease
NCT06488209 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Test How Well BI 3000202 is Tolerated by People With Type 1 Interferonopathies
NCT06878365 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Efficacy and Safety of Efavaleukin Alfa in Subjects With Active Systemic Lupus Erythematosus
NCT04680637 ·Status: TERMINATED ·Phase: PHASE2
-
Phase I Clinical Study of GC012F Injection in Treatment of Refractory Systemic Lupus Erythematosus
NCT05846347 ·Status: UNKNOWN ·Phase: PHASE1
-
Anti-infection of Low-does IL-2 in SLE
NCT02932137 ·Status: COMPLETED ·Phase: NA
-
A Study of CellCept (Mycophenolate Mofetil) in Patients With Lupus Nephritis.
NCT00425438 ·Status: TERMINATED ·Phase: PHASE3
-
Study of ARO-CFB in Adult Healthy Volunteers
NCT06209177 ·Status: COMPLETED ·Phase: PHASE1
-
Effectiveness of Pharmaceutical Care in the Adherence of Systemic Lupus Erythematosus Treatment
NCT02330250 ·Status: COMPLETED ·Phase: NA
-
A Phase 1/2a Study of DB-2304 in Healthy Adults and SLE Participants
NCT06625671 ·Status: RECRUITING ·Phase: PHASE1/PHASE2